ABSTRACT
Background
and Purpose:
Sepsis-induced acute kidney injury (AKI) and acute lung injury (ALI)
have high morbidity and mortality, with no effective clinically
available drugs. Anti-inflammation is effective strategy in the therapy
of AKI and ALI. NF-κB is a target for the development of
anti‑inflammatory agents. The purpose of the study is to evaluate the
effect of 270, self-developed NF-κB inhibitor, in LPS-induced AKI and
ALI.